The evolution and clinical relevance of prognostic classification systems in myelofibrosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The evolution and clinical relevance of prognostic classification systems in myelofibrosis
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 5, Pages 681-692
Publisher
Wiley
Online
2015-12-30
DOI
10.1002/cncr.29842
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
- (2015) Brady L. Stein et al. Journal of the National Comprehensive Cancer Network
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
- (2015) F Palandri et al. LEUKEMIA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis
- (2014) Klaus Geissler et al. AMERICAN JOURNAL OF HEMATOLOGY
- Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter
- (2014) Giovanni Barosi BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Changing myelofibrosis's natural course at last
- (2014) S. Verstovsek BLOOD
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
- (2014) J.-C. Hernandez-Boluda et al. HAEMATOLOGICA
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
- (2014) G Barosi et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Novel myelofibrosis treatment strategies: potential partners for combination therapies
- (2014) B L Stein et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
- (2014) A Tefferi et al. LEUKEMIA
- CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
- (2014) M C Finazzi et al. LEUKEMIA
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
- (2014) A Tefferi et al. LEUKEMIA
- Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
- (2013) J. A. Kennedy et al. BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia
- (2013) T Barbui et al. LEUKEMIA
- Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
- (2013) E Tenedini et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
- (2013) Giovanni Barosi et al. PLoS One
- Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
- (2012) T. Barbui et al. BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Improving Survival Trends in Primary Myelofibrosis: An International Study
- (2012) Francisco Cervantes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
- (2011) A. Tefferi et al. BLOOD
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
- (2011) T. Klampfl et al. BLOOD
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
- (2011) G Finazzi et al. LEUKEMIA
- Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
- (2011) A Pardanani et al. LEUKEMIA
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
- (2011) A Tefferi et al. LEUKEMIA
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients
- (2010) P. Morel et al. BLOOD
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence
- (2010) Francesco Passamonti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
- (2010) M. A. Elliott et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
- (2010) R Jäger et al. LEUKEMIA
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
- Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
- (2010) Anthony Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
- (2009) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
- (2009) K. Hussein et al. BLOOD
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
- (2009) C. S. Tam et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
- (2009) Mrinal M. Patnaik et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- (2009) Constantine S. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
- (2008) F. Passamonti et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
- (2008) P. Guglielmelli et al. HAEMATOLOGICA
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- (2008) A Tefferi et al. LEUKEMIA
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
- (2008) F Cervantes et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search